CG Oncology (CGON) Common Equity (2023 - 2026)

CG Oncology (CGON) has 4 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 54.92% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 54.92% YoY), and the FY2025 full-year result was $752.6 million, up 2.62% from the prior year.
• Common Equity for Q1 2026 stood at $1.1 billion, up from $752.6 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q1 2026 and bottomed at -$123.1 million in Q4 2023.
• The 4-year median for Common Equity is $568.9 million (2024), against an average of $452.6 million.
• The widest annual swing landed in 2024, when Common Equity jumped 760.66%; it then gained 2.62% in 2025.
• A 4-year view of Common Equity shows it stood at -$123.1 million in 2023, then jumped by 695.76% to $733.4 million in 2024, then gained by 2.62% to $752.6 million in 2025, then jumped by 45.07% to $1.1 billion in 2026.
• The last three Common Equity figures came in at $1.1 billion (Q1 2026), $752.6 million (Q4 2025), and $687.6 million (Q3 2025), per Business Quant data.

Peer Comparison